-
Something wrong with this record ?
Blood transcriptome responses in patients correlate with severity of COVID-19 disease
Y. Wang, K. Schughart, TM. Pelaia, T. Chew, K. Kim, T. Karvunidis, B. Knippenberg, S. Teoh, AL. Phu, KR. Short, J. Iredell, I. Thevarajan, J. Audsley, S. Macdonald, J. Burcham, A. McLean, PREDICT-19 consortium, B. Tang, M. Shojaei
Language English Country Switzerland
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Grant support
U19 AI100625
NIAID NIH HHS - United States
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- MeSH
- COVID-19 * genetics MeSH
- Humans MeSH
- Neutrophils MeSH
- SARS-CoV-2 MeSH
- Gene Expression Profiling MeSH
- Transcriptome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infected individuals display a wide spectrum of disease severity, as defined by the World Health Organization (WHO). One of the main factors underlying this heterogeneity is the host immune response, with severe COVID-19 often associated with a hyperinflammatory state. AIM: Our current study aimed to pinpoint the specific genes and pathways underlying differences in the disease spectrum and outcomes observed, through in-depth analyses of whole blood transcriptomics in a large cohort of COVID-19 participants. RESULTS: All WHO severity levels were well represented and mild and severe disease displaying distinct gene expression profiles. WHO severity levels 1-4 were grouped as mild disease, and signatures from these participants were different from those with WHO severity levels 6-9 classified as severe disease. Severity level 5 (moderate cases) presented a unique transitional gene signature between severity levels 2-4 (mild/moderate) and 6-9 (severe) and hence might represent the turning point for better or worse disease outcome. Gene expression changes are very distinct when comparing mild/moderate or severe cases to healthy controls. In particular, we demonstrated the hallmark down-regulation of adaptive immune response pathways and activation of neutrophil pathways in severe compared to mild/moderate cases, as well as activation of blood coagulation pathways. CONCLUSIONS: Our data revealed discrete gene signatures associated with mild, moderate, and severe COVID-19 identifying valuable candidates for future biomarker discovery.
Centre for Clinical Research in Emergency Medicine Royal Perth Bentley Group Perth WA Australia
Department of Intensive Care Medicine Nepean Hospital Penrith NSW Australia
Department of Microbiology St George Hospital Kogarah NSW Australia
Emergency Department Royal Perth Hospital Perth WA Australia
Institute of Molecular Virology University of Münster Münster Germany
Medical School University of Western Australia Perth WA Australia
School of Chemistry and Molecular Biosciences The University of Queensland Brisbane QLD Australia
Sydney Informatics Hub Core Research Facilities The University of Sydney Sydney NSW Australia
Sydney Institute for Infectious Disease The University of Sydney Sydney NSW Australia
Westmead Hospital Western Sydney Local Health District Westmead NSW Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004542
- 003
- CZ-PrNML
- 005
- 20230425171604.0
- 007
- ta
- 008
- 230418s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fimmu.2022.1043219 $2 doi
- 035 __
- $a (PubMed)36741372
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Wang, Ya $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia $u Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia $u Faculty of Medicine and Health, Sydney Medical School Nepean, Nepean Hospital, University of Sydney, Penrith, NSW, Australia
- 245 10
- $a Blood transcriptome responses in patients correlate with severity of COVID-19 disease / $c Y. Wang, K. Schughart, TM. Pelaia, T. Chew, K. Kim, T. Karvunidis, B. Knippenberg, S. Teoh, AL. Phu, KR. Short, J. Iredell, I. Thevarajan, J. Audsley, S. Macdonald, J. Burcham, A. McLean, PREDICT-19 consortium, B. Tang, M. Shojaei
- 520 9_
- $a BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infected individuals display a wide spectrum of disease severity, as defined by the World Health Organization (WHO). One of the main factors underlying this heterogeneity is the host immune response, with severe COVID-19 often associated with a hyperinflammatory state. AIM: Our current study aimed to pinpoint the specific genes and pathways underlying differences in the disease spectrum and outcomes observed, through in-depth analyses of whole blood transcriptomics in a large cohort of COVID-19 participants. RESULTS: All WHO severity levels were well represented and mild and severe disease displaying distinct gene expression profiles. WHO severity levels 1-4 were grouped as mild disease, and signatures from these participants were different from those with WHO severity levels 6-9 classified as severe disease. Severity level 5 (moderate cases) presented a unique transitional gene signature between severity levels 2-4 (mild/moderate) and 6-9 (severe) and hence might represent the turning point for better or worse disease outcome. Gene expression changes are very distinct when comparing mild/moderate or severe cases to healthy controls. In particular, we demonstrated the hallmark down-regulation of adaptive immune response pathways and activation of neutrophil pathways in severe compared to mild/moderate cases, as well as activation of blood coagulation pathways. CONCLUSIONS: Our data revealed discrete gene signatures associated with mild, moderate, and severe COVID-19 identifying valuable candidates for future biomarker discovery.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a COVID-19 $x genetika $7 D000086382
- 650 _2
- $a transkriptom $7 D059467
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a neutrofily $7 D009504
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Schughart, Klaus $u Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States $u Institute of Molecular Virology, University of Münster, Münster, Germany
- 700 1_
- $a Pelaia, Tiana Maria $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia
- 700 1_
- $a Chew, Tracy $u Sydney Informatics Hub, Core Research Facilities, The University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Kim, Karan $u Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia
- 700 1_
- $a Karvunidis, Thomas $u Medical ICU, 1st Department of Internal Medicine, Charles University and Teaching Hospital, Pilsen, Czechia
- 700 1_
- $a Knippenberg, Ben $u Department of Microbiology. St George Hospital, Kogarah, NSW, Australia
- 700 1_
- $a Teoh, Sally $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia
- 700 1_
- $a Phu, Amy L $u Research and Education Network, Western Sydney Local Health District, Westmead Hospital, NSW, Westmead, Australia $u Faculty of Medicine and Health, Sydney Medical School Westmead, Westmead Hospital, University of Sydney, NSW, Westmead, Australia
- 700 1_
- $a Short, Kirsty R $u School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
- 700 1_
- $a Iredell, Jonathan $u Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Westmead, NSW, Australia $u Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia $u Westmead Hospital, Western Sydney Local Health District, Westmead, NSW, Australia $u Sydney Institute for Infectious Disease, The University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Thevarajan, Irani $u Victorian Infectious Disease Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia $u Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
- 700 1_
- $a Audsley, Jennifer $u Victorian Infectious Disease Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia $u Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia
- 700 1_
- $a Macdonald, Stephen $u Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Royal Perth Hospital, Perth, WA, Australia $u Medical School, University of Western Australia, Perth, WA, Australia $u Emergency Department, Royal Perth Hospital, Perth, WA, Australia
- 700 1_
- $a Burcham, Jonathon $u Centre for Clinical Research in Emergency Medicine, Royal Perth Bentley Group, Perth, WA, Australia
- 700 1_
- $a McLean, Anthony $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia $u Faculty of Medicine and Health, Sydney Medical School Nepean, Nepean Hospital, University of Sydney, Penrith, NSW, Australia
- 700 1_
- $a Tang, Benjamin $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia $u Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia
- 700 1_
- $a Shojaei, Maryam $u Department of Intensive Care Medicine, Nepean Hospital, Penrith, NSW, Australia $u Centre for Immunology and Allergy Research, The Westmead Institute for Medical Research, Westmead, NSW, Australia $u Faculty of Medicine and Health, Sydney Medical School Nepean, Nepean Hospital, University of Sydney, Penrith, NSW, Australia
- 710 2_
- $a PREDICT-19 consortium
- 773 0_
- $w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 1043219
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36741372 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171600 $b ABA008
- 999 __
- $a ok $b bmc $g 1924938 $s 1190751
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 13 $c - $d 1043219 $e 20230120 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
- GRA __
- $a U19 AI100625 $p NIAID NIH HHS $2 United States
- LZP __
- $a Pubmed-20230418
